Recently Eastern Capital Ltd increased Its Position In Tapimmune Inc

May 16, 2018 - By Sheila Anderson

TapImmune, Inc. (NASDAQ:TPIV) Corporate Logo

Eastern Capital Ltd posted increased Interest in Tapimmune Inc

Eastern Capital Ltd filed with SEC a SC 13D/A form about Tapimmune Inc. The form can be accessed here: 000140840818000005.The Eastern Capital Ltd’s stake increased by 24.53 % for 5,300,002 shares.On May14, 2018 Eastern Capital Ltd has 38.8% of the stock.

And that’s Why Eastern Capital Ltd Holds Tapimmune Inc

Item 4.Purpose of Transaction

On May 14, 2018, Eastern CapitalLimited entered into a Common Stock Purchase Agreement with the Issuer to purchase 1,300,000 shares of common stock at a priceper share of $2.40.

The Reporting Persons acquiredthe Issuer’s securities for investment purposes.

The Reporting Persons currentlyhave no plans or proposals which relate to or would result in any transaction, event or action enumerated in paragraphs (a) through(j) of Item 4 of Schedule 13D.

CUSIP No. 876033408 Page 6 of 8

TPIV touched $3.26 during the last trading session after $0.23 change.TapImmune, Inc. is downtrending after having declined 26.26% since May 17, 2017. TPIV has 153,209 volume or 262.58% up from normal. TPIV underperformed the S&P 500 by 37.81%.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease.The firm is valued at $34.64 million. It specializes in the development of immunotherapies targeting women's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers.Currently it has negative earnings. The company's peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

For more TapImmune, Inc. (NASDAQ:TPIV) news brought out briefly go to: Prnewswire.com, Prnewswire.com, Prnewswire.com, Prnewswire.com or Benzinga.com. The titles are as follows: “TapImmune to Present at 2018 NYC Oncology Investor Conference” brought out on May 07, 2018, “TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics” on May 15, 2018, “TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform” with a publish date: May 16, 2018, “TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference” and the last “32 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: May 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.